866-997-4948(US-Canada Toll Free)

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 40 Pages

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 1, 2, 1 and 1 respectively.

Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Heterozygous familial hypercholesterolemia (heFH) - Overview 5
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 14
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 15
Daewoong Co Ltd 15
Esperion Therapeutics Inc 15
Gemphire Therapeutics Inc 16
Madrigal Pharmaceuticals Inc. 16
Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles 17
(bempedoic acid + ezetimibe) - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
gemcabene calcium - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
MGL-3196 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
MGL-3745 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ST-103 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 30
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products 31
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 32
Featured News & Press Releases 32
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 32
Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit 33
Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 35
May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196 35
Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 36
Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 13
Number of Products by Stage and Molecule Type, H2 2017 14
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H2 2017 15
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, H2 2017 15
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Gemphire Therapeutics Inc, H2 2017 16
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 16
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2017 30
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2017 31

List of Figures
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Stage and Molecule Types, H2 2017 14

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *